May 11

Cannabotech raised NIS 1.2 million in a public offering

May 10

Together achieved an export permission from Germany to UK

January 20

Panaxia reports the first export of cannabis tablets to France as part of the pilot in which it participates and is expected to last about two years. The tablets were delivered to France free of charge.

January 22

Togther reports that the Securities Authority has initiated administrative enforcement proceedings against it in respect of its previous reports from 2018 and 2019 regarding business relations with China.

Recent News

May 17, 2022

Revenue growth is expected to continue in the second quarter and throughout 2022 due to organic growth, acquisition of ‘Better’, and international expansion…

April 25, 2022

Cronos and Intercure have similar EV and revenue, but the profitability is very different …

April 7, 2022

The medical cannabis market in Israel is one of the fastest growing in the world. According to data published by the Israeli Medical Cannabis…

March 16, 2022

Sales will begin after Cann10 receives regulatory approval from the Brazilian Ministry of Health ANVIZA for the marketing and sale of the company’s products…

Clever Leaves will cultivate InterCure’s strains to launch InterCure’s EU-GMP compliant branded products within the EU, UK and South American markets

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on telegram
Share on email

InterCure (NASDAQ: INCR) and Clever Leaves (NASDAQ: CLVR) today announced the execution of an exclusive multi-year cultivation, marketing and distribution agreement.

Over the term of the Agreement, InterCure will have access to Clever Leaves’ highTHC medical cannabis flower to serve several medical cannabis markets, including the Israeli market. As part of the partnership, Clever Leaves will cultivate InterCure’s high quality strains to launch InterCure’s EU-GMP compliant branded products within the EU, UK and South American markets.

This is an excellent agreement for InterCure, as it will allow it to manufacture its brands in Europe, in a facility with a GMP-EU standard, without any set-up costs of such facilities, and without the long period of time it would have taken it to set up such facilities itself.

Also, the agreement does not contain minimum quantities for production or import for which Intercure undertakes.

Clever Leaves shares dropped about 90% in the past year and are traded on the Nasdaq at a value of about $ 30 million.

This type of agreement proves the high branding of Israeli companies in Europe. It proves that even companies like Clever Leaves, which has its own brands, prefer to promote Israeli brands in the European market.

“Establishing exclusive long-term strategic partnerships with world-class partners supports our international expansion plans and profitable growth strategy” says Alex Rabinovitch, CEO, InterCure, adding “we are proud to partner with Clever Leaves, a pioneering multinational operator which shares our commitment of providing high quality pharmaceutical grade medical cannabis products to patients around the globe.”

Pursuant to the Agreement, Clever Leaves and InterCure agreed to collaborate on certain technical matters for the development of new products in an attempt to satisfy the needs of patients in different countries.

“We are enthusiastic for partnering with InterCure, a company with multinational presence and strong leadership position in Israel”, said Andrés Fajardo, President and incoming CEO of Clever Leaves, adding “InterCure’s high-quality standards, their knowledge and experience in genetics and developing new products, as well as their strong distribution network, will potentialize Clever Leaves’ plans to bring the benefits of medical cannabis to different geographies around the world, including Israel.”

Share your thoughts, add a comment

Your email address will not be published.